Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.79 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.79 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.79 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.79 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.79 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.79 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.79 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.79 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | F13A1 | P00488 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7280705 | 0.97 | HDAC3 (0.77) | LMNATSHRHDAC3HDAC1HDAC2 | |
| SCHEMBL7441298 | 0.95 | HDAC3 (0.79) | LMNATSHRHDAC3HDAC1HDAC2 | |
| SCHEMBL7441870 | 0.95 | HDAC3 (0.79) | LMNATSHRHDAC3HDAC1HDAC2 | |
| SCHEMBL7436977 | 0.95 | HDAC3 (0.79) | LMNATSHRHDAC3HDAC1HDAC2 | |
| SCHEMBL4074353 | 0.95 | HDAC3 (0.87) | LMNATSHRHDAC3HDAC1HDAC2 | |
| SCHEMBL8355337 | 0.92 | LMNA (0.91) | LMNATSHRHDAC3HDAC1HDAC2 | |
| SCHEMBL8359273 | 0.90 | LMNA (1.00) | LMNATSHRHDAC3HDAC1HDAC2 | |
| SCHEMBL166980 | 0.89 | L3MBTL1 (0.71) | LMNATSHRHDAC3HDAC1HDAC2 | |
| SCHEMBL13073412 | 0.89 | HDAC3 (0.78) | LMNATSHRHDAC3HDAC1HDAC2 | |
| SCHEMBL8356049 | 0.88 | LMNA (0.85) | LMNATSHRHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2017-06-29 | — | — | US | disclosed |
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2017-06-29 | — | — | US | disclosed |
| EP-3118211-A1 | AMIDE COMPOUNDS AND METHODS FOR THE PRODUCTION AND USE THEREOF | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2017-01-18 | — | — | EP | disclosed |
| WO-2014018913-A2 | SANTACRUZAMATE A COMPOSITIONS AND ANALOGS AND METHODS OF USE | UNIVERSITY OF CONNECTICUT (US) | 2014-01-30 | — | — | WO | disclosed |
| US-4939147-A | Substituted 3,4-dihydroxy phenylethylamino compounds | FISONS PLC. (GB) | 1990-07-03 | — | — | US | disclosed |
| US-4922022-A | Substituted 3,4-dihydroxy phenylethylamino compounds | FISONS PLC (GB) | 1990-05-01 | — | — | US | disclosed |
| EP-0314725-A1 | 2-(3,4-DIHYDROXYPHENYL)ETHYLAMINES, THEIR PREPARATION AND USE AS PHARMACEUTICAL | FISONS plc (GB) | 1989-05-10 | — | — | EP | disclosed |
| WO-1988009326-A1 | 2-(3,4-DIHYDROXYPHENYL)ETHYLAMINES, THEIR PREPARATION AND USE AS PHARMACEUTICAL | FISONS PLC (GB) | 1988-12-01 | — | — | WO | disclosed |
| EP-0292202-A1 | 2-(3,4-Dihydroxyphenyl ethyl amines, their preparation and use as pharmaceutical compounds | FISONS plc (GB) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | ACE, ACE2, MCTS1 | LMNA 129/4885TSHR 2783/4885HDAC3 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.